STOCK TITAN

2022 Fourth Quarter Earnings Conference Call Tuesday, February 14, 2023, 5:00 p.m. ET

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

BETHLEHEM, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, February 14, 2023.

February 14, 2023 schedule:

4:05 p.m. ET – 2022 fourth quarter financial results press release will be distributed.

Prior to the call - To participate in the teleconference, go to the following link to register and the teleconference number and PIN for the teleconference will be sent to you:

https://register.vevent.com/register/BIf712ba49243f46c7a741f490d1ea19a4 

5:00 p.m. ET - Conference call and simultaneous webcast begins.

The conference call will also be available via webcast, and may be accessed on the investor relations page of OraSure’s website, www.orasure.com. Please click on the webcast link and follow the prompts for registration and access, 10 minutes prior to the call.

If you are unable to participate, the webcast will be archived on OraSure’s website shortly after the call has ended and will be available for 14 days.

Investor Contact:
Scott Gleason
SVP Investor Relations & Corporate Communications Communications
484-425-0588
sgleason@orasure.com
Media Contact:
Amy Koch
Sr. Mgr. Corporate Communications
484-523-1815
media@orasure.com

 


OraSure Technologies Inc

NASDAQ:OSUR

OSUR Rankings

OSUR Latest News

OSUR Stock Data

420.80M
67.02M
3.66%
92.9%
3.87%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
BETHLEHEM

About OSUR

based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo